Recently, Beijing Ansong Technology Co., Ltd. proudly announced the successful completion of a new financing round, raising nearly 150 million yuan. This latest funding round has drawn support from notable investors, including Yizhuang Venture Capital, Galaxy Innovation Capital, as well as existing shareholders Saiying Capital and Mifang Health Fund. The capital raised will be strategically allocated to bolster research and development efforts, expand production capacity, facilitate clinical and market outreach, and foster the construction of a robust industrial ecosystem.

Established in 2017 by leading industry experts, Ansong Technology has carved out a niche in the orthopedic medical device sector, with its cutting-edge ceramic material technology serving as its cornerstone. The company has secured registration certificates for its zirconia and alumina ceramic femoral heads. Its products, having undergone rigorous clinical follow-up verification, boast an impressive 0% breakage rate and have successfully penetrated the international market. Moreover, Ansong Technology has proactively applied for numerous patents, invested in state-of-the-art production equipment, and set up two major ceramic production lines. Both its factory premises and workshops adhere to Good Manufacturing Practice (GMP) standards, ensuring the highest quality and safety.

Zhang Jifeng, Chairman of Ansong Technology, expressed his vision for the future, stating that the company will remain steadfast in its commitment to innovation in high-performance medical ceramic materials. By consolidating and expanding its competitive edge in the field of orthopedic implants, Ansong Technology aims to offer global solutions for medical ceramic materials, thereby elevating the localization level and enhancing the global competitiveness of high-end medical devices.